Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients.

ABSTRACT:

Background

We examined clinical outcomes in a population-based cohort of EGFR mutant advanced NSCLC patients, exploring the potential role of factors including tumour EGFR mutation fraction and cellularity in predicting outcomes.

Methods

A cohort of patients with EGFR mutant advanced NSCLC was identified (N =2 93); clinical outcomes, pathologic and treatment details were collected. Tumour response was determined from radiology and clinical notes. Association between demographic and pathologic variables EGFR TKI response, time to treatment failure (TTF) and overall survival (OS) was examined using logistic regression and proportional hazards regression. EGFR TKI response rates were summarised by percent mutation fraction to explore their association.

Results

Higher mut

SUBMITTER: Martin P 

PROVIDER: S-EPMC4800294 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature